Category: Cannabinoid (GPR55) Receptors

In daily scientific practice, intolerance towards the TKIs could hinder the QoL in individuals with CML,29 and to be able to improve QoL, monitoring for and managing adverse events (AEs) from the TKIs promptly and maintaining the individuals adherence towards the TKI treatment could optimize affected individual outcomes.23 The comorbidities impact on selecting the TKI […]